Henry J. Fuchs, M.D. joined 博彩平台网址大全 in March 2009 and currently serves as our President of Worldwide Research & Development. From December 2009 to October 2016, Hank served as our Executive Vice President and Chief Medical Officer. From March 2009 to December 2009, Hank served as our Senior Vice President and Chief Medical Officer.

From September 2005 until December 2008, Hank served as Executive Vice President and Chief Medical Officer for Onyx Pharmaceuticals Inc., a biopharmaceutical company. Hank served as CEO of Ardea Biosciences, Inc. from January 2003 until June 2005. Hank first joined Ardea Biosciences, Inc. as Vice President, Clinical Affairs in October 1996 and was appointed President and Chief Operating Officer in November 2001. From 1987 to 1996, Hank held various positions at Genentech, Inc. where, among other responsibilities, he led the clinical program that resulted in the approval of Pulmozyme, a therapeutic for cystic fibrosis. Hank was also responsible for the Phase III development program that led to the approval of Herceptin to treat metastatic breast cancer.

Hank received an M.D. from George Washington University and a B.A. in biochemical sciences from Harvard University. Hank previously served as a director of Mirati Therapeutics, Inc., a public biopharmaceutical company, and was formerly on the board of Genomic Health, Inc., a public molecular diagnostics company, until its acquisition by Exact Sciences in November 2019.